The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).
Andrew B. Nixon
Research Funding - Roche
Susan Halabi
No relevant relationships to disclose
Ivo Shterev
No relevant relationships to disclose
Mark Starr
No relevant relationships to disclose
John C Brady
No relevant relationships to disclose
Janice P. Dutcher
No relevant relationships to disclose
Judith O. Hopkins
No relevant relationships to disclose
Herbert Hurwitz
Consultant or Advisory Role - Bayer; Genentech; Regeneron; Roche; Sanofi
Honoraria - Roche
Research Funding - Genentech; GlaxoSmithKline; Roche; Sanofi
Eric Jay Small
No relevant relationships to disclose
Brian I. Rini
No relevant relationships to disclose
Phillip G. Febbo
No relevant relationships to disclose
Daniel J. George
Consultant or Advisory Role - Genentech
Research Funding - Genentech